Exar Corp. (NYSE:EXAR) shares advanced 1.38% in last trading session and ended the day at $5.87. EXAR Gross Margin is 40.40% and its has a return on assets of -6.20%. Exar Corp. (NYSE:EXAR) quarterly performance is 14.65%.
Exar Corporation (NYSE: EXAR), a leading supplier of analog mixed-signal products serving the industrial, high-end consumer and infrastructure markets, announces the XR18910, the latest addition to its family of analog front end sensor interfaces, which integrates high channel count and functionality in a tiny 3.5mm x 3.5mm footprint. The XR18910 provides 14-bit signal path linearity and is designed to connect analog sensors to a microcontroller (MCU) or field-programmable gate array (FPGA) with an embedded ADC.
Abbott Laboratories (NYSE:ABT) ended the last trading day at $43.97. Company weekly volatility is calculated as 1.46% and price to cash ratio as 10.60. Abbott Laboratories (NYSE:ABT) showed a weekly performance of 1.43%.
Abbott Laboratories (NYSE: ABT) reported Q1 EPS of $0.41, $0.02 better than the analyst estimate of $0.39. Revenue for the quarter came in at $4.9 billion versus the consensus estimate of $4.78 billion. Abbott sees FY2016 EPS of $2.14 – $2.24, versus prior guidance of $2.10 – $2.20 and the consensus of $2.16.
On 20 April, Silicon Laboratories Inc. (NASDAQ:SLAB) shares advanced 1.43% and was closed at $45.34. SLAB EPS growth in last 5 year was -15.20%. Silicon Laboratories Inc. (NASDAQ:SLAB) year to date (YTD) performance is -6.59%.
Silicon Laboratories Inc. (NASDAQ:SLAB) announced that it plans to release first quarter 2016 financial results on Wednesday, April 27, 2016. An earnings conference call will follow the release at 7:30 a.m. Central Time.
Onconova Therapeutics, Inc. (NASDAQ:ONTX) shares advanced 4.22% in last trading session and ended the day at $0.48. ONTX has a return on assets of -84.20%. Onconova Therapeutics, Inc. (NASDAQ:ONTX) quarterly performance is -27.36%.
Onconova Therapeutics, Inc. (NASDAQ:ONTX), announced the presentation of pre-clinical data for its first-in-class dual inhibitor of ARK5 and CDK4/6 at the 2016 AACR Annual Meeting being held April 16-20, 2016 at the Ernest N. Morial Convention Center in New Orleans, LA.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) caters to the Healthcare space. It has a net profit margin of 8.00% and weekly performance is 1.65%. On the last day of trading company shares ended up at $56.56. Teva Pharmaceutical Industries Limited (NYSE:TEVA) distance from 50-day simple moving average (SMA50) is 1.24%.
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced that it will release its first quarter 2016 financial results on Monday, May 9, 2016 at 7:00 a.m. ET.
Leave a Reply